Chatham Capital Group Inc. Purchases 8,770 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Chatham Capital Group Inc. raised its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 21.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,229 shares of the medical instruments supplier’s stock after acquiring an additional 8,770 shares during the period. Chatham Capital Group Inc. owned approximately 0.22% of LeMaitre Vascular worth $3,267,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. increased its holdings in LeMaitre Vascular by 18.6% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 6,342 shares of the medical instruments supplier’s stock valued at $421,000 after acquiring an additional 993 shares during the last quarter. Annex Advisory Services LLC grew its stake in shares of LeMaitre Vascular by 5.3% in the 1st quarter. Annex Advisory Services LLC now owns 26,149 shares of the medical instruments supplier’s stock worth $1,735,000 after buying an additional 1,315 shares in the last quarter. Bridge City Capital LLC grew its stake in shares of LeMaitre Vascular by 2.7% in the 1st quarter. Bridge City Capital LLC now owns 73,204 shares of the medical instruments supplier’s stock worth $4,858,000 after buying an additional 1,890 shares in the last quarter. Congress Asset Management Co. MA grew its stake in shares of LeMaitre Vascular by 12.0% in the 1st quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock worth $44,201,000 after buying an additional 71,411 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in shares of LeMaitre Vascular by 28.3% in the 1st quarter. Los Angeles Capital Management LLC now owns 22,505 shares of the medical instruments supplier’s stock worth $1,493,000 after buying an additional 4,960 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock remained flat at $82.28 during trading hours on Friday. 410,783 shares of the company’s stock traded hands, compared to its average volume of 124,148. The company has a market cap of $1.85 billion, a price-to-earnings ratio of 54.49, a P/E/G ratio of 2.51 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $84.15. The business’s 50-day simple moving average is $76.45 and its 200-day simple moving average is $66.73.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The company had revenue of $53.48 million during the quarter, compared to analysts’ expectations of $51.50 million. During the same period in the previous year, the company earned $0.27 EPS. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. Research analysts forecast that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th were issued a $0.16 dividend. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.78%. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. JMP Securities lifted their price objective on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research note on Friday, May 3rd. Barrington Research lifted their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $100.00 price target on shares of LeMaitre Vascular in a research note on Friday, May 31st. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $77.57.

Insider Activity

In related news, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the transaction, the chief executive officer now directly owns 2,079,128 shares in the company, valued at approximately $156,558,338.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CEO George W. Lemaitre sold 68,906 shares of the business’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the sale, the chief executive officer now directly owns 2,133,428 shares of the company’s stock, valued at $161,500,499.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO George W. Lemaitre sold 8,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $75.30, for a total value of $602,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,079,128 shares in the company, valued at $156,558,338.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 87,431 shares of company stock worth $6,627,520. 10.79% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.